Concert Health, a leading behavioral health medical group, today announced a collaboration with Mass General Brigham, an integrated academic health care system, to expand behavioral health services delivered through primary care.
The launch program will be rolled out in Mass General Brigham’s primary care facilities throughout Massachusetts, giving more than 400 primary care providers and their patients access to Concert Health’s behavioral health services.Collaborative care is an evidence-based approach to identifying and treating patients with behavioral health conditions such as anxiety and depression in primary care settings.
Concert Health was created to facilitate the integration of comprehensive behavioral health services into primary care on a large scale. Its distinctive approach and technology platform simplify the process for major healthcare systems and medical groups to incorporate its services into their overall care offerings. With an impressive team of nearly 200 highly skilled clinicians, Concert Health provides both patients and healthcare providers with remote access to behavioral health professionals, including psychiatrists and care managers. This access is available through primary care providers, pediatricians, and OB/GYNs within 24-48 hours. To date, Concert Health has provided care for over 70,000 patients, with 55% of them covered by Medicaid and Medicare.
Share this article Harpoon’s T-cell are engineered antibodies that redirect T cells to attack cancer cells. Image credit: Shutterstock/Meletios Verras. MSD has entered a definitive
Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments
Mass General Brigham, Concert Health Collaborate to Expand Behavioral Health Services for Primary Care
by Syed Hamza Sohail Leave a Comment
What You Should Know:
MSD acquires Harpoon for $680m to strengthen T-cell engager armoury – Pharmaceutical Technology
Share this article Harpoon’s T-cell are engineered antibodies that redirect T cells to attack cancer cells. Image credit: Shutterstock/Meletios Verras. MSD has entered a definitive
One Size Doesn’t Fit All for Automated BP Measurement Cuffs, Trial Finds
Using a “regular” size arm cuff with an automated blood pressure (BP) device for all adults resulted in inaccurate BP readings regardless of arm size,
Ultima Genomics launching high-end DNA sequencers that can read genome for $100
Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments